First came supplements. Then wearables. Then optimization. Now biology itself is becoming the frontier.
Peptides, metabolic therapies, mitochondrial science, precision diagnostics and longevity research—separated from hype by evidence.
A searchable field guide to therapeutic, investigational and emerging peptides—organized by what we know, what we don’t and why people care.
Recovery, metabolic health, cognition, sleep, longevity and performance—then compare the strength of evidence behind each compound.
A separate lane for what biohackers are discussing, trying and reporting online. Selected priority profiles now include dated, source-linked public-discussion samples—kept distinct from clinical evidence.
The research, regulation and market forces reshaping biohacking right now.
Litigation, platform pressure and FDA enforcement are reshaping access to investigational peptides outside the laboratory. We separate those market developments from questions of clinical efficacy.
Open the Retatrutide profile →The compounds where science, community momentum, regulation and market activity are changing fastest.
Substantial human trial interest, huge community demand, investigational status and an accelerating enforcement battle are converging around one molecule.
Few compounds better demonstrate the distance between online adoption and clinical validation.
A useful reminder that strong evidence can still be narrow and indication-specific.
A mature evidence base provides a benchmark for the emerging metabolic frontier.
Compelling human biology research, but a much thinner case for exogenous intervention.
Put two compounds side by side across human evidence, preclinical depth, regulatory status and community momentum.
Features, field guides and research briefs that explain the movement around the molecules.
Popularity, mechanism, animal data, human trials and regulatory status are different signals. We show them separately.
See our methodology